EN | UA
EN | UA

Help Support

Back

CYP2D6 and CYP2C9 found to predict analgesic efficacy of ketorolac and tramadol

CYP2D6 and CYP2C9 found to predict analgesic efficacy of ketorolac and tramadol CYP2D6 and CYP2C9 found to predict analgesic efficacy of ketorolac and tramadol
CYP2D6 and CYP2C9 found to predict analgesic efficacy of ketorolac and tramadol CYP2D6 and CYP2C9 found to predict analgesic efficacy of ketorolac and tramadol

What's new?

For postoperative pain management, the pain-relieving effectiveness of ketorolac and tramadol can be predicted by CYP2D6 and CYP2C9.

As per the findings of a study, CYP2D6 and CYP2C9 gene polymorphisms can forecast the analgesic effectiveness of a combination of ketorolac and tramadol in people undergoing video laparoscopic cholecystectomy. This assessment was carried out to investigate the possible link of CYP2D6 and CYP2C9 polymorphisms with safety and efficacy of ketorolac and tramadol in postsurgery pain.

Overall, 107 participants were genotyped for CYP2C9 and CYP2D6 polymorphisms and underwent laparoscopic cholecystectomy. Assessment of postsurgery pain relief was done. Postoperative pain syndrome was examined utilizing McGill pain questionnaire and visual analogue scale (VAS). Dynamics of red blood counts evaluated adverse effects profile as a potential stimulus for eliciting gastrointestinal bleeding as per the global evaluation of triggers.

As noted, there was a substantial drop in pain in CYP2C9*2 carriers, based on VAS: after 12 h - by 1.5; after 24 h - by 1.1; after 36 h - by 1.05; after 48 h - by 0.7. The outcomes were not significant in CYP2C9*3 carriers. In carriers of CYP2D6*4, the pain syndromes were greater at all-time intervals. However, statistically reliable results were procured only after two h - by 1.01 and after 24 h - by 0.8.

For NSAIDs, the profile of adverse effects was explored by the dynamics of erythrocyte and hemoglobin indices. Considerable decline was witnessed in relative difference in hemoglobin levels in CYP2C9*3 and CYP2C9*2 polymorphism carriers by 2.2 and 1.7, respectively. CYP2C9 can anticipate gastrointestinal bleeding risk, including those hidden to ketorolac, concluded the study investigators.

Source:

Drug Metabolism and Personalized Therapy

Article:

The effect of CYP2D6 and CYP2C9 gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy

Authors:

Andranik Alexandrovich Muradian et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: